Revenue was down 4 percent due to divestments and adverse currencies. Operating income was 17 percent lower at €322 million, driven by adverse price/mix developments. Specialty Chemicals were impacted by a general softening of demand across all markets. Cash from operating activities was €261 million (2012: €351 million), mainly due to lower operating income.
Summary of financial outcomes
|
2nd quarter |
|
|
|
January - June | ||||||||
|
2012 |
2013 |
Δ% |
in € millions |
2012 |
2013 |
Δ% | ||||||
|
4,044 |
3,865 |
(4) |
Revenue |
7,751 |
7,330 |
(5) | ||||||
|
388 |
322 |
(17) |
Operating income |
624 |
539 |
(14) | ||||||
|
9.6 |
8.3 |
|
ROS% |
8.1 |
7.4 |
| ||||||
|
|
|
|
|
|
|
| ||||||
|
|
|
|
Invested capital |
12,684 |
10,239 |
| ||||||
|
|
|
|
Moving average ROI (in %) |
8.7 |
7.7 |
| ||||||
|
|
|
|
|
|
|
| ||||||
|
554 |
474 |
(14) |
EBITDA |
964 |
849 |
(12) | ||||||
|
166 |
168 |
|
Capital expenditures |
301 |
299 |
| ||||||
|
351 |
261 |
|
Net cash from operating activities |
(353) |
(145) |
| ||||||
|
|
|
|
Net debt |
2,844 |
2,197 |
| ||||||
|
|
|
|
|
|
|
| ||||||
|
215 |
308 |
43 |
Net income from continuing operations |
325 |
404 |
24 | ||||||
|
4 |
121 |
|
Net income from discontinued operations |
(22) |
114 |
| ||||||
|
219 |
429 |
96 |
Net income attributable to shareholders |
303 |
518 |
71 | ||||||
|
0.92 |
1.78 |
|
Earnings per share from total operations (in €) |
1.28 |
2.15 |
| ||||||
|
1.06 |
1.37 |
|
Adjusted earnings per share (in €) |
1.71 |
1.89 |
| ||||||
|
|
|
|
Number of employees |
52,820 |
50,500 |
| ||||||